Contract manufacturer Delpharm has reached a CAD $60m agreement with the Canadian Government to modernise its injectable manufacturing facility in Boucherville.
The site, which is responsible for the production of sterile injectable generic medicines, will secure the Canadian supply chain and ensure that hospitals have access to essential generic products for surgery and intensive care.
The $200m modernisation plan will result in the site's expansion, as well as the installing of a new filling line.
Delpharm will also upgrade 95% of the facility's equipment to comply with new Health Canada standards.
The strategic move will preserve more than 500 skilled jobs in Quebec, while ensuring that the Canadian supply chain is robust.
The Boucherville plant currently produces 20 of the 100 critical medicines vital to the Canadian healthcare system, making it a key part of the nation's pharmaceutical supply chain.
The signing of a 10-year agreement between Delpharm and generic pharmaceutical company Sandoz establishes a foundation for ensuring a stable and reliable supply of critical medicines for Canadians, thereby enhancing the country’s healthcare autonomy amid global supply chain disruptions.
“This significant investment is a key step in securing Canada’s industrial biomanufacturing footprint and strengthening our resilience against future health emergencies and supply chain disruptions," commented Anita Anand, Minister of Innovation, Science and Industry for the Canadian Government.
"By increasing our domestic capacity to produce essential sterile injectables, we are ensuring that Canadians are best positioned to have access to the medicines they need."
"Our $60m contribution not only supports innovation in the biomanufacturing sector, but also reinforces Canada's health security and economic resilience," she concluded.